Tuesday, 17 June 2008

Monday, 16 June 2008

Clinical Trial started

Clinical Trial has now started and the results will be available at the end of the trial. We would like to thank all parties who have supported the project.

Thursday, 13 March 2008

Nordic Partnership presents Unclassified EIGA PHARMA ONLINE PRESENTATION Monday FRIDAY 30th May 2008 Europe 11.00 am GMT USA 3PM GMT 2008

Click here to enter presentation for 30th May no software required.

Dial conference number on +44 (0) 207 193 3604 or

If you have skype please click here or

add nordicpartnershipltd to your skype.

Help line please call 44(0) 207 385 1331

Unclassified presentation will last for 30 mins with questions for a further 10 mins, allow a total of 40 mins.

Presentation Agenda

1. Introduction to the team and professional advisors

2. Scientific presentation

3. Corporate structure

4. Source and application of funds summary

5. Summary of the opportunity

6. Questions

Your will need the following:-

1. Computer online with high speed access broad band

2. Sound and working microphone

2. A working internet browser

3. Software downloaded from skype web site (takes 1 mins to install) and add nordicpartnershipltd to your skype contacts

EIGA PHARMA would like to thank its sponsors Nordic Partnership Ltd and Instant presenter for assisting with this presentation.

Friday, 7 March 2008

Eiga Pharma gives Nordic Partnership Ltd Exclusive Mandate to raise £5 million

Nordic Partnerhsip Ltd has been given an exclusive mandate to assist Eiga with the development of the Eiga Project which includes The Nano Particle Magnetic Separator & application of protein complex for cancer treatment and diagnostics and to raise funds for the Eiga Project by building the professional team of advisors.

Disclaimer

The information contained on this web site is not an invitation or solicitation to invest in the shares of the company. It is produced for the purpose of description of the activities of the company, the research, the products and treatments. Any use of this information for the purpose of a financial transaction should be conducted through an independent financial advisor or professional consultant.

Jonathan de Rin, Ruben Berg, Anjam Butt and Gavin Pell are working on:-

Due diligence materials
Advisory Board
Key material agreements
Clinical trial outsourcing
Private Placement memorandum
Corporate structure
IP transfer agreement
Share holder agreement
Pathfinder strategy to eventually list the company on the London AIM market

EIGA PHARMA PROJECT BACKGROUND

The teams work is based on the original ideas developed by Judah Folkman in the field of angiogenesis. The team has developed proprietry research in the field of cancer treatment, diagnostics and a specific Magnet Nano Particle Separation device.

Judah Folkman our Hero has sadly died

Eiga Team would like to thank Judah for all his kind help and support on our project and he will be sadly missed

Judah Folkman MD 1933-2008

Please click here and take the time to watch a small selection of these videos that will help you to understand the work of Judah Folkman

Click here to see a "Thank you for saving my life"

Click here for a Memoriam to a Giant of Cancer therapy

EIGA PHARMA RESEARCH, PRODUCTS AND INVENTIONS

The Eiga team's work is centered around three principal areas.

Magnetic Nano Particle Separator
Cancer diagnostics
Autoimmune response of cancer

1. Magnetic Nano Particle Separator

Magnetic Separator device is protected by patent

The invention relates to the field of ecology, biotechnology, molecular biology, biological chemistry, immunology, in particular to detection of components with the help of specific interactions between the latter and a microcarrier comprising a receptor immobilized thereon for defining said components. Increasing the reliability of simultaneous detection of a number of components in a mixture, making the analysis cheaper and less time-consuming, extending the range of markers used as well as providing the possibility of visual registration of the contents of a number of components in a mixture is achieved by a method and a device for simultaneous detection of a number of components in a mixture, said method comprising a step of reacting of the components under analysis with the specific receptors immobilized on the surfaces of microcarriers of various forms. As a result of formation of specific complexes a mobility of microcarriers under the influence of a physical field is changed. Due to the change of mobility of microcarriers under the influence of a physical field a separation into a fraction of non-reacted microcarriers with unchanged mobility, and a fraction or fractions of microcarriers with changed mobility. Since each type of a specific receptor is bound to its marked microcarrier the analysis of just a marker characteristic of microcarriers with changed mobility under the influence of a physical field will reveal the availability of the component which has reacted with this microcarrier in the mixture under analysis. Under a physical field as in the case described a gravitation field, an electric field or a magnetic field as well as combinations of .the above is understood. A more efficient reacting of the mixture components with a minimum amount of microcarriers , provision of an efficient and operation-saving separation of microcarriers is achieved in a convenient for sterilization separating chamber where the process of retaining the microcarriers on the walls of a separating chamber and removing them into the collector is actually continuous.

2005 discovery made

Method and device for simultaneous detection of multiple components in a mixture.

Document Type and Number

Europea Patent EP1365241

Code A2

Treatment method and diagnostics for early cancer are protected by patent application.

Protein complexes for prevention and treatment of diseases with angiogenesis disorders.

Doucment Type and Number

Wipo Patent WO/2008/006187

Code A2

2.Cancer diagnostics
3. Autoimmune response of cancer

The invention relates to the medical field, and in particular, to protein complexes and application thereof for the correction of autoimmune processes in human or animal bodies and also to a research of biochemical mechanisms of diseases with angiogenesis disorders. The protein complexes claimed comprise an antigen and an effector portion attached thereto wherein said antigen presents an angiogenic factor. An angiogenic factors of a protein complexes could be both pro-angiogenic and anti-angiogenic. An effector portion can either show of immunomodulating activity, or provide the specific influence on a target immunocompetent cells Moreover, it can be made in the form of a polymer carrier for depleting of target autoantibodies and immunocompetent cells. There are also claimed the use of new protein complexes, the new methods of treatment of diseases with angiogenesis disorders and a new method and a new test-system for monitoring of angiogenesis disorders for use in the above methods of treatment. The inventors are emphasizing the role of autoimmune mechanism in origin of malignant growth and the importance of subject of the invention for early cancer diagnostics, prevention and treatment

Started clinical trials Feb 2007

Friday, 22 February 2008

EIGA INVESTORS

Click here to see executive summary of the project

Investors may wish to attend a web conference where the EIGA PHARMA RESEARCH TEAM will be giving a live presentation every Friday at 11am GMT for Europe and 3pm for USA GMT and will be able to answer questions after the conference.

courtesy of Kidica

EIGA PHARMA SWITZERLAND AG 30% of the equity £5.5m

EIGA PHARMA OPERATIING COMPANY PLC 50% of equity £50m

Disclaimer

EIGA PHARMA CLINICAL TRIALS

EIGA PHARMA is currently speaking to a number of parties to assist with clinical trials click here for for example

Glossary of terms for clinical trials

What are the different types of clinical trials?

Treatment trials test experimental treatments, new combinations of drugs, or new approaches to surgery or radiation therapy.

Prevention trials look for better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vaccines, vitamins, minerals, or lifestyle changes.

Diagnostic trials are conducted to find better tests or procedures for diagnosing a particular disease or condition.

Screening trials test the best way to detect certain diseases or health conditions.

Quality of Life trials (or Supportive Care trials) explore ways to improve comfort and the quality of life for individuals with a chronic illness.

What are the phases of clinical trials?

Clinical trials are conducted in phases. The trials at each phase have a different purpose and help scientists answer different questions:

Preclinical Trials

These are normally conducted on animals, clinical trials are defined as trials on humans.

In Phase I trials, researchers test an experimental drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

In Phase II trials, the experimental study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.

In Phase III trials, the experimental study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.

In Phase IV trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.

Understanding Clinical Trials

Choosing to participate in a clinical trial is an important personal decision. The following frequently asked questions provide detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

What is a clinical trial?

Although there are many definitions of clinical trials, they are generally considered to be biomedical or health-related research studies in human beings that follow a pre-defined protocol. ClinicalTrials.gov includes both interventional and observational types of studies. Interventional studies are those in which the research subjects are assigned by the investigator to a treatment or other intervention, and their outcomes are measured. Observational studies are those in which individuals are observed and their outcomes are measured by the investigators.

Why participate in a clinical trial?

Participants in clinical trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research.

Who can participate in a clinical trial?

All clinical trials have guidelines about who can participate. Using inclusion/exclusion criteria is an important principle of medical research that helps to produce reliable results. The factors that allow someone to participate in a clinical trial are called "inclusion criteria" and those that disallow someone from participating are called "exclusion criteria". These criteria are based on such factors as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. Before joining a clinical trial, a participant must qualify for the study. Some research studies seek participants with illnesses or conditions to be studied in the clinical trial, while others need healthy participants. It is important to note that inclusion and exclusion criteria are not used to reject people personally. Instead, the criteria are used to identify appropriate participants and keep them safe. The criteria help ensure that researchers will be able to answer the questions they plan to study.

What happens during a clinical trial?

The clinical trial process depends on the kind of trial being conducted (See What are the different types of clinical trials?) The clinical trial team includes doctors and nurses as well as social workers and other health care professionals. They check the health of the participant at the beginning of the trial, give specific instructions for participating in the trial, monitor the participant carefully during the trial, and stay in touch after the trial is completed.

Some clinical trials involve more tests and doctor visits than the participant would normally have for an illness or condition. For all types of trials, the participant works with a research team. Clinical trial participation is most successful when the protocol is carefully followed and there is frequent contact with the research staff.

What is informed consent?

Informed consent is the process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study. If the participant's native language is not English, translation assistance can be provided. Then the research team provides an informed consent document that includes details about the study, such as its purpose, duration, required procedures, and key contacts. Risks and potential benefits are explained in the informed consent document. The participant then decides whether or not to sign the document. Informed consent is not a contract, and the participant may withdraw from the trial at any time.

What are the benefits and risks of participating in a clinical trial?

Benefits

Clinical trials that are well-designed and well-executed are the best approach for eligible participants to:
Play an active role in their own health care.
Gain access to new research treatments before they are widely available.
Obtain expert medical care at leading health care facilities during the trial.
Help others by contributing to medical research.
Risks

There are risks to clinical trials.
There may be unpleasant, serious or even life-threatening side effects to experimental treatment.
The experimental treatment may not be effective for the participant.
The protocol may require more of their time and attention than would a non-protocol treatment, including trips to the study site, more treatments, hospital stays or complex dosage requirements.

What are side effects and adverse reactions?

Side effects are any undesired actions or effects of the experimental drug or treatment. Negative or adverse effects may include headache, nausea, hair loss, skin irritation, or other physical problems. Experimental treatments must be evaluated for both immediate and long-term side effects.

How is the safety of the participant protected?

The ethical and legal codes that govern medical practice also apply to clinical trials. In addition, most clinical research is federally regulated with built in safeguards to protect the participants. The trial follows a carefully controlled protocol, a study plan which details what researchers will do in the study. As a clinical trial progresses, researchers report the results of the trial at scientific meetings, to medical journals, and to various government agencies. Individual participants' names will remain secret and will not be mentioned in these reports (See Confidentiality Regarding Trial Participants).

What should people consider before participating in a trial?

People should know as much as possible about the clinical trial and feel comfortable asking the members of the health care team questions about it, the care expected while in a trial, and the cost of the trial. The following questions might be helpful for the participant to discuss with the health care team. Some of the answers to these questions are found in the informed consent document.
What is the purpose of the study?
Who is going to be in the study?
Why do researchers believe the experimental treatment being tested may be effective? Has it been tested before?
What kinds of tests and experimental treatments are involved?
How do the possible risks, side effects, and benefits in the study compare with my current treatment?
How might this trial affect my daily life?
How long will the trial last?
Will hospitalization be required?
Who will pay for the experimental treatment?
Will I be reimbursed for other expenses?
What type of long-term follow up care is part of this study?
How will I know that the experimental treatment is working? Will results of the trials be provided to me?
Who will be in charge of my care?

What kind of preparation should a potential participant make for the meeting with the research coordinator or doctor?
Plan ahead and write down possible questions to ask.
Ask a friend or relative to come along for support and to hear the responses to the questions.
Bring a tape recorder to record the discussion to replay later.
Every clinical trial in the U.S. must be approved and monitored by an Institutional Review Board (IRB) to make sure the risks are as low as possible and are worth any potential benefits. An IRB is an independent committee of physicians, statisticians, community advocates, and others that ensures that a clinical trial is ethical and the rights of study participants are protected. All institutions that conduct or support biomedical research involving people must, by federal regulation, have an IRB that initially approves and periodically reviews the research.

Does a participant continue to work with a primary health care provider while in a trial?

Yes. Most clinical trials provide short-term treatments related to a designated illness or condition, but do not provide extended or complete primary health care. In addition, by having the health care provider work with the research team, the participant can ensure that other medications or treatments will not conflict with the protocol.

Can a participant leave a clinical trial after it has begun?

Yes. A participant can leave a clinical trial, at any time. When withdrawing from the trial, the participant should let the research team know about it, and the reasons for leaving the study.

Where do the ideas for trials come from?

Ideas for clinical trials usually come from researchers. After researchers test new therapies or procedures in the laboratory and in animal studies, the experimental treatments with the most promising laboratory results are moved into clinical trials. During a trial, more and more information is gained about an experimental treatment, its risks and how well it may or may not work.

Who sponsors clinical trials?

Clinical trials are sponsored or funded by a variety of organizations or individuals such as physicians, medical institutions, foundations, voluntary groups, and pharmaceutical companies, in addition to federal agencies such as the National Institutes of Health (NIH), the Department of Defense (DOD), and the Department of Veteran's Affairs (VA). Trials can take place in a variety of locations, such as hospitals, universities, doctors' offices, or community clinics.

What is a protocol?

A protocol is a study plan on which all clinical trials are based. The plan is carefully designed to safeguard the health of the participants as well as answer specific research questions. A protocol describes what types of people may participate in the trial; the schedule of tests, procedures, medications, and dosages; and the length of the study. While in a clinical trial, participants following a protocol are seen regularly by the research staff to monitor their health and to determine the safety and effectiveness of their treatment.

What is a placebo?

A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the experimental treatment's effectiveness. In some studies, the participants in the control group will receive a placebo instead of an active drug or experimental treatment.

What is a control or control group?

A control is the standard by which experimental observations are evaluated. In many clinical trials, one group of patients will be given an experimental drug or treatment, while the control group is given either a standard treatment for the illness or a placebo.

EIGA OBJECTIVES

To open a cancer treatment Clinic in Switzerland - Eiga Clinic 2009.
After clinical trials we will license local companies to produce the diagnostic service.
To obtain distribution agreement for the diagnostic test.
The Nano Magnetic Separation will go into production and be sold and distributed to research centers and medical clinics.

WHAT ARE WE CURRENTLY WORKING ON

Nano Magnetic particle Separator - The Eiga team has patented a Nano Magnetic Particle. The device has a large number of leading edge medical applications in the separation of foreign bodies or contaminate particles from the blood.

Complex Protein for cancer treatment - The Eiga team has identified a core complex of proteins that can inhibit the growth of a cancer tumour particularly in the instance of solid tumors. The proteins act to stimulate the bodies own natural ability to reduce the blood supply to the cancer tumours.

Early stage Cancer Diagnostics - A marker protein has successfully been tested in the laboratory with an elisa test showning a high probability of the presence of cancer.

Currently undertaking clinical trials in Russia - Clinical trial have been undertaken on terminal cancer patients and have shown positive results. Some patients have experienced a decrease in the growth of the tumour and in others a recovery was observed.

EIGA TEAM

From left to right

Yuri Legeev, Oleg Nikolaevich Darashkevich, A.M. Olovnikov, Eugene I Goufman

EIGA PHARMA ADVISORY BOARD

Dr Leonard Hayflick

Dr. Leonard Hayflick was born on 20 May 1928 in Philadelphia, Pa. He received his Ph.D. at the University of Pennsylvania in 1956. After receiving a post-doctoral Fellowship for study at the University of Texas, Galveston, under the tutelage of the renowned cell culturist Prof. Charles M. Pomerat, he returned to Philadelphia, where he spent ten years as an Associate Member of the Wistar Institute and two years as an Assistant Professor of Research Medicine at the University of Pennsylvania.

In 1968 Dr. Hayflick was appointed Professor of Medical Microbiology at the Stanford University School of Medicine, Stanford, California. In 1982 he moved to the University of Florida, Gainesville, where he became Director of the Center for Gerontological Studies and Professor of Zoology in the College of Liberal Arts and Sciences and Professor of Microbiology and Immunology in the College of Medicine.

In 1988 Dr. Hayflick joined the faculty of the University of California, San Francisco where he is presently Professor of Anatomy. Dr. Hayflick is a member of numerous national and international scientific and public boards of directors and committees. He is now, or has been, on the Editorial Boards of more than ten professional journals. Dr. Hayflick was Editor-in-Chief of the international journal “EXPERIMENTAL GERONTOLOGY” for 13 years.

He is a member of twenty scientific and professional societies in which he has held several high offices including President of the Gerontological Society of America from 1982 to 1983. He was a founding member of the Council of the National Institute on Aging, NIH and Chairman of its' Executive Committee. He was a consultant to the National Cancer Institute and the World Health Organization, and is now a member of several scientific advisory boards. He was Chairman of the Scientific Review Board of the American Federation for Aging Research where he was also a Vice President and a Member of the Board of Directors.

Dr Michael B Fossel M.D., Ph.D

Michael B. Fossel, M.D., Ph.D. (born 1950, Greenwich, Connecticut) is a professor of clinical medicine at Michigan State University best known for his views on telomerase therapy as a possible treatment forcellular senescence. Fossel has appeared on many major news programs to discuss aging and appears regularly on National Public Radio (NPR). He is also a respected lecturer, author, and the founder and former editor-in-chief of the Journal of Anti-Aging Medicine (now known as Rejuvenation Research).

Prior to earning his M.D. at Stanford Medical School, Fossel earned a joint B.A. (cum laude) and M.A. in psychology at Wesleyan University and a Ph.D. in neurobiology at Stanford University. He is also a graduate of Phillips Exeter Academy. After graduating from medical school in 1981, he was awarded a National Science Foundation fellowship and taught at Stanford University.

In addition to his current position at Michigan State University, Fossel has lectured at the National Institute for Health, the Smithsonian Institution, and at various other universities and institutes in various parts of the world. Fossel is a fellow of the American College of Emergency Physicians, a member of the American Association for the Advancement of Science, the American Gerontological Society, the American Society on Aging, and the American Geriatrics Society, and serves on the board of directors for the American Aging Association.

Fossel has written numerous articles on aging and ethics for the Journal of the American Medical Association and In Vivo, and a book by Fossel entitled Reversing Human Aging was published in 1996. The book garnered favorable reviews from mainstream newspapers as well as Scientific American and has since been published in six languages. An academic textbook by Fossel entitled Cells, Aging, and Human Diseasewas published in 2004 by Oxford University Press.

Since his days as a teacher at Stanford University, Fossel has studied aging from a medical and scientific perspective with a particular emphasis on premature aging syndromes such as progeria, and since at least 1996 he has been a strong and vocal advocate of experimenting with telomerase therapy as a way of treating diseases, disorders, and syndromes such as progeria, Alzheimer's disease, atherosclerosis,osteoporosis, cancer, AIDS, and organic senescence (i.e., aging). However, he is careful to qualify his advocacy of telomerase therapy as being a potential treatment for these conditions rather than a "cure for old age" and a panacea for age-related medical conditions, albeit a potential treatment that could radically extend the maximum human life span and reverse the aging process in most people. Specifically, Fossel sees the potential of telomerase therapy as being a highly effective point of intervention in a wide variety of medical conditions.

EIGA PHARMA RESEARCH TEAM

A.M. Olovnikov, PhD

First name: Alexey

Middle name: Matveevich

EDUCATION

Graduated from Moscow State University (biochemistry).

PhD (1966) in Immunochemistry was made in Department of Immunology and Oncology (head of Dept was Prof. Lev A. Zilber) and granted by the Scientific Counsel of Gamaleya Institute for Epidemology and Microbiology of Academy of Medical Sciences of the USSR. Scientific supervisor was Prof. Aaron. E. Gurvich. Theme of Ph.D. Thesis: "The detection of antigens and antibodies using immunosorbents".

PROFESSIONAL APPOINTMENT

1959 Senior technician , then Junior Investigator in Gamaleya

Institute for Epidemology and Microbiology of Academy of Medical Sciences (Department of Immunology and Oncology and Laboratory of Antibody

biosynthesis. Then Senior researcher in the 2 Medical Institute and Institute for biological trials of chemical compounds Themes: Immunochemical diagnostics and antibody formation studies

and theoretical biology studies.

1977 Senior researcher in the Institute for Chemical Physics of Academy of Sciences of the USSR. Themes: Development of immunochemical techniques and theoretical biological studies.

1996 - present. Senior researcher, then Leading researcher in Institute of Biochemical Physics of Russian Academy of Sciences. Themes: Theoretical Biology studies.

Main directions of scientific investigations are as follows: generation and elaboration of hypotheses aimed at explanation of molecular and cellular mechanisms of main still unsolved questions of biology of aging, cell differentiation, morphogenesis, peculiarities of nuclear envelop functioning, regulation of infradian rhythms and control of the flow of biological time in organism.

A short outline of some Olovnikov’s scientific contributions

In 1971-1973, A.M. Olovnikov made an contribution into foundation of a biological area, that is called a telomere biology. The essence of this novel scientific direction consists in the study of mechanisms of shortening of telomeric DNA in normal somatic cells, as well as the study of the biological role of this shortening and pathways of maintenance of stability of chromosome tips in germline and somatic cells, stem cells and cancer cells including. These studies are now performed in dozens of labs around the world and they were started just after the wortldwide recognition of the existence of the process of telomeric DNA shortening which was firstly predicted in Olovnikov's theoretical publications. On the whole, A.M. Olovnikov performed in the telomere biology the following:

1) it was firstly formulated the very existence of the problem of the DNA

end underreplication (In 1971 , in Doklady, see in Bibliography);

2) it was explained that a circular form of genome of prokaryotes is a means of

protection of their DNA from the end underreplication;

3) it was predicted the existence of the process of DNA shortening at the tips of chromosomal DNA during doubling of normal somatic cells. On this basis, it was interpreted the existence of a Hayflick limit, or the restricted potential of doublings of the normally aging somatic cells;

4) it was predicted the existence of correlation between cellular senescence and telomere DNA shortening;

5) it was also predicted the existence of special form of compensatory DNA polymerase in germline cells (now it is called as a telomerase) which is responsible for the maintenance of the stable length of telomere DNA;

6) it was proposed that cancer cells should have the same DNA polymerase (telomerase) as the germline cells, and it was predicted that this DNA polymerase (that is a telomerase) does endow the cancer cells with their immortality, allowing them to avoid a Hayflick limit and cell senescence.

In 1992-1995, Olovnikov put forward, the conception of an another effect, namely so called "DNA terminal underrepair synthesis", or shortly "end underrepair".

In 1997-1999 Olovnikov proposed and theoretically elaborated the mechanism of quantitative regulation of genes’ expression via the so called fountain mechanism of RNA-dependent regulation of ion channels in inner membrane of nuclear envelope.

In 2003-2006, Olovnikov proposed the principally novel mechanism of biological aging (in frame of the so called redusome hypothesis) and then, on its basis, it was developed the hypothesis of a chronomere program of life span. Besides it was suggested an existence of novel physiological system, so called lunasensor system.

In 2007, it was proposed a new hypothesis concerning the origin of Alzheimer’s disease.

List of Olovnikov's publications

(some Russian publications were also published in English)

1. Гурвич А.Е., Оловников А.М. Сравнение антигенных свойств чистых антител и неспецифических гамма-глобулинов. Биохимия, том 25, вып. 4, 646-652 (1960).

2. Оловников А.М. Изготовление иммуносорбентов на основе эмульсионного неизотактического полистирола. Лабор. дело, № 8, 31-34 (1962).

3. Оловников А.М. Поликонденсированный суспензионный антитело-иммуносорбент и его использование в реакции агглютинации для определения содержания антигенов. ДАН СССР, том 158, № 5, 1202-1205 (1964).

4. Оловников А.М. Использование иммуносорбентов для определения абсолютных количеств гаптенов и антигенов. Биохимия, том 29, вып. 4, 680-684 (1964).

5. Оловников А.М. Получение иммуносорбентов в виде суспензии бензидин-белковых комплексов и использование их для определения антител методом агглютинации. Вопр. мед. химии, том 10, вып. 5, 538-542 (1964).

6. Оловников А.М. Определение содержания антигенов по агглютинации эритроцитов, покрытых поликонденсированными тетразотатом диаминодифениламина белками антисыворотки. ДАН СССР, том 169, № 5, 1180-1183 (1966).

7. Оловников А.М., Гурвич А.Е. Изучение антигенных свойств белково-целлюлозного иммуносорбента. Вопр. мед. химии, том 12, вып. 1, 112-115 (1966).

8. Olovnikov A.M., Gurvich A.E. Immunization with protein-cellulose co-polymer (immunosorbent). Nature, vol. 209, № 5021, 417- 419 (1966).

9. Olovnikov A.M. Sensitization of erythrocytes by polycondensed proteins of immune serum and their use for determining antigen content. Immunochemistry, 4, 77-80 (1967).

10. Оловников А.М. Методы иммунохимического анализа. ЖВХО им. Менделеева, том. 13, № 4, 445-452 (1968).

11. Оловников А.М. Определение содержания антигенов. Метод агглютинации ПБИС-эритроцитов и метод агглютинации частиц поликонденсированного антителоиммуносорбента. В книге: "Иммунохимичепский анализ", под ред. Л.А. Зильбера, Изд-во Медицина, Москва , стр. 68-78 (1968).

12. Оловников А.М., Цветков В.С. Обнаружение эмбрионального альфа-глобулина методом агрегат-гемагглютинации в сыворотке больных при некоторых формах рака человека. Бюлл. эксп. биол. мед. , том 68, №12,102-104 (1969).

13. Оловников А.М., А.А. Корукова. Использование стабильной соли тетразония для сенсибилизации белками эритроцитов при постановке локального пассивного гемолиза. Бюлл. эксп. биол. мед. , №12, 106-108 (1970).

14. Абелев Г.И., Цветков В.С., Бирюлина Т.И., Эльгорт Д.А., Оловников А.М., Гусев А.И., Язова А.К., Перова С.Д., Рубцов И.В., Шаборина С.В., Канторович Б.А., Тур В.М., Хазанов А.И.,Левина Д.М.. Оценка применения высокочувствительных методов определения альфа-фетопротеина для диагностики гепатоцеллюлярного рака и тератобластом. Бюлл. эксп. биол. мед. , № 4, 75-81 (1971).

15. Оловников А.М. Принцип маргинотомии в матричном синтезе полинуклеотидов. Доклады АН СССР, 201, № 6, 1496-1499 (1971). (Olovnikov A.M. (1971). Principles of marginotomy in template synthesis of

polynucleotides. Doklady Biochem. vol. 201, 394-397.).

16. Оловников А.М. Иммунный ответ и процесс маргинотомии в лимфоидных клетках. Вестник АМН СССР, № 12, 85-87 (1972).

17. Olovnikov, A.M. A theory of marginotomy: The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. vol. 41, 181-190 (1973).

18. Idelson L.I., Olovnikov A.M., Koifman M.M., Gorina L.I. Application of high sensitivity aggregate hemagglutination test for autoimmune hemolytic anemia with negative antiglobuline serum test. Vox sanguinis. № 6 (1976).

19. Горина Л.Г., Флуер Ф.С., Оловников А.М., Езепчук Ю.В. Высокочувствительное определение экзо-энтеротоксина Bacillus cereus методом агрегат-гемагглютинации. Журн. гиг. эпид.,микр. и иммунол. , том 20, № 3, 337-343 (1976).

20. Чирков С.Н., Оловников А.М., Сургучева Н.А., Оловникова Н.И., Пирузян Л.А., Кулинич А.В., Атабеков И.Г. Виробактериальная агглютинация (АБВ-тест)- новый метод иммунодиагностики вирусов сельскохозяйственных растений. Доклады ВАСХНИЛ. № 7, 9-11 (1981).

21. Чирков С.Н., Оловников А.М., Варицев Ю.А., Атабеков И.Г. Диагностика X, S, M и Y вирусов картофеля методом виробактериальной агглютинации. Сельскохозяйственная биология, том 17, № 2, 272-277 (1982).

22. Оловников А.М. Компьютена в механизме развития. Онтогенез, том 14, № 1, 106-107 (1983).

23. Chirkov S.N., Olovnikov A.M., Surguchyova N.I., Atabekov J.G. Immunodiagnosis of plant viruses by a virobacterial agglutination test. Ann. appl. Biol. , № 104, 477-483 (1984).

24. Оловников А.М., Койфман М.М., Оловникова Н.И. Гемобактериальная агглютинация - метод определения антиэритроцитарных антител. Бюлл. эксп. биол. мед. № 9, 373-375 (1985).

25. Оловников А.М. Старение есть результат укорочения "дифферотены" в теломере из-за концевой недорепликации и недорепарации ДНК. Известия АН СССР. Серия биол. № 4, 641-643 (1992).

26. Оловников А.М. Об эффекте концевой недорепарации, или неполной репарации конца линейной двуспиральной молекулы ДНК. Известия АН. Серия биол.,№4, 501-503 (1995).

27. Оловников А.М. О роли неполной репарации конца хромосомной ДНК в старении нейронов и постмитотических организмов. Известия РАН. Серия биол.,№4,504-507 (1995 ).

28. Оловников А.М. О возможности использования клетками эффекта концевой недорепарации ДНК в контроле за правильной последовательностью событий в индивидуальном развитии. Онтогенез , том 26, № 3, 254-256 (1995).

29. Оловников А.М. О парадоксе: малая продолжительность жизни при длинных теломерах . Онтогенез, том 26 , № 4, 332-334 (1995).

30. Olovnikov AM Telomeres, telomerase, and aging: origin of the theory. Experimental Gerontology, vol. 31, 443-448 (1996 )

31. Оловников А.М. Молекулярный механизм морфогенеза: теория локационной ДНК. Биохимия, том 61, № 11, 1948-1970 (1996).

32. Olovnikov AM (1997) Towards the quantitative traits regulation: fountain theory implications in comparative and developmental biology. Int. J. Dev. Biol. 41, 923-931.

33. Оловников А.М. (1998) Пседозатравки вызывают соматическое гипермутирование Ig-генов. Биохимия, 63(12):1702-1703.

34. Olovnikov A.M. (1999) The telomere shortening signal may be explained by a fountain mechanism modulating the expression of eukaryotic genes. J.Anti-Aging Medicine, 2 (1) 59-74.

35. Оловников А.М. (1999) Старение как универсальная хроническая “болезнь количественных признаков”: клеточное старение и РНК-зависимая ионная модуляция продуктивности генов. Успехи геронтологии (Санкт-Петербург), 3, 54-64.

36. Оловников А.М. (1999). Заметки о «принтомерном» механизме клеточной памяти и ионной регуляции конфигураций хроматина. Биохимия, 64, №12, 1689-1698.

37. Kipling D, Wynford-Thomas D, Jones CJ, Akbar A, Aspinall R, Bacchetti S, Blasco MA, Broccoli D, DePinho RA, Edwards DR, Effros RB, Harley CB, Lansdorp PM, Linskens MH, Prowse KR, Newbold RF, Olovnikov AM, Parkinson EK, Pawelec G, Ponten J, Shall S, Zijlmans M, Faragher RG . (1999). Telomere-dependent senescence. Nat Biotechnol 17(4):313-314.

38. Оловников А.М. (2001). Внутриядерные ионные фонтаны как регуляторы работы генома: фонтанная гипотеза доминантности и некоторых эпигенетических эффектов. Молекулярная биология. 35: 163-176.

39. Оловников А.М. (2003). Редусомная гипотеза старения и контроля биологического времени в индивидуальном развитии. Биохимия. 68 (1): 7-41. Olovnikov AM. The redusome hypothesis of aging and the control of biological time during individual development. Biochemistry (Mosc). 2003 Jan;68(1):2-33.

40. Оловников А.М. (2003). Редусомное старение: комментарии. Успехи геронтологии (СПб). 12: 28-45.

41. Olovnikov A. Role of Hypothetical Nuclear Organelles - Redusomes - in Morphogenesis, Aging and Cancer. (2004). In: Frontiers in Neurodegenerative Disorders and Aging: Fundamental Aspects, Clinical Perspectives and New Insights. Ozben T. and Chevion M. (Eds.), IOS Press, NATO Science Series. Series I: Life and Behavioural Sciences -Vol. 358, Pp. 89-98. Amsterdam, Berlin, Oxford. etc.

42. Оловников А.М. (2005) Принтомерная гипотеза морфогенеза: создавая эмбрион, клетки синтезируют транзиторные «перихромосомные» ДНК-содержащие органеллы, необходимые для интерпретации позиционной информации. Геофизические процессы и биосфера. том. 4., №1/2, 62-70.

43. Оловников А.М. Создавая эмбрион, клетки синтезируют транзиторные «перихромосомные» ДНК-содержащие органеллы, необходимые для интерпретации позиционной информации. В книге: "Химическая и биологическая кинетика. Новые горизонты. Том 2. Биологическая кинетика: Сб. обзорных статей". Москва, изд-во "Химия". (2005), 496-512.

44. Olovnikov A.M. (2005). When creating an embryo, cells are synthesizing transitory “perichromosomal” DNA-containing organelles necessary for interpreting positional information. Pp. 465-480. In: Chemical and Biological Kinetics New Horizons. Vol. 2: Biological Kinetics. In commemoration of Professor N.M. Emanuel's 90th Anniversary. Edited by E.B. Burlakova, S.D. Varfolomeev. Koninklijke Brill NV, Leiden, The Netherlands.

45. Оловников А.М. 2005. Редумера как недостающее звено в понимании старения человека. Клиническая геронтология. 11: 50-69.

46. Olovnikov A. Lunasensor, infradian rhythms, telomeres, and the chronomere program of aging. Annals of the New York Academy of Sciences. 2005, 1057: 112-132.

47. Olovnikov A. Chronobiology and chronomeres. In: Trends in Chronobiology Research. (Editor: Frank Columbus). 2006. Nova Science Publishers, Inc. New York. Pp.49-61.

48. Оловников А.М. Роль парагенома в развитии организмов. Онтогенез, 2007, том 38, № 2, с. 1-23.

49. Olovnikov A.M. Hypothesis: Lifespan is regulated by chronomere DNA of the hypothalamus. Journal of Alzheimer’s Disease. 2007, 11: 241-252.

Membership in Editorial boards of journals:

1) Advances in Gerontology (SPb, Russia);

2) Ontogenez (Russian Journal of Developmental Biology)(Russia)

3) Rejuvenation Research (editorial board)

4) Journal of Alzheimer’s disease (Associate Editor)

5) Current Aging Science (Bentham Science Publishers) (Associate Editor)

6) The Open Aging Journal (Bentham Science Publishers) (Associate Editor)

7) Current Gerontology and Geriatrics Research (Associate Editor)

PERSONAL

Marital status: Married, two sons

Place of birth: Vladivostok, Far East of Russia

Citizenship: Russia

Eugene I. Goufman

EDUCATION: M.D.: Semashko’s Moscow StateMedical Institute, 1980 Ph. D. in Cell Biology; Institute of Experimental Endocrinology, Academy of Medical Sciences of USSR,

PROFESSIONAL EXPERIENCE:

1999 – 2006 Orekhovich Institute of Biomedical Chemistry, department of proteomics, Russian Academy of Medical Sciences, Moscow, Russia

1995-1999 Visiting Scientist University of Illinois at Chicago Department of Genetics

Chicago, Illinois

1995-1997 Recipient of support from the NCI Oncology Research Faculty Development Program

1988-1994 Senior Staff Scientist Laboratory of Experimental Morphology Institute of Experimental Endocrinology, Russian Academy of Medical Sciences, Moscow

1983-1988 Ph.D. thesis research with Dr. Akmayev, Institute of Experimental Endocrinology, Academy of Medical Sciences of the USSR. Thesis title: the “Functional morphology of paraventricular nuclei under normal conditions and experimental disturbances of carbohydrate metabolism”

1981-1983 Post-graduate internship: Study of central neural regulation of the endocrine pancreas.

SUMMARY OF QUALIFICATIONS

· Experienced in tissue culture technology including culturing mammalian and insect cell lines.

· Experienced in introduction genes utilizing viruses , Lipofectins and calcium-mediated DNA transfection.

· Experienced in morphological, immuno-histochemical and serological techniques used to investigate pathomorphology of damaged tissues.

· Experienced in molecular biology techniques such as PCR, RT-PCR for cloning, site directed mutagenesis, and gel retardation assays, immunoprecipitation and western blot.

· Experienced in protein purification techniques and protein analysis using column chromatography and SDS-PAGE.

· Experienced in proteomics technics (2-D electrophoresis, chromatography, MALDI-TOFmass spectrometry).

PUBLICATIONS

1.Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, Serebryakova MV, Toropygin IY, Vlasova MA, Safarova MR, Makarov OV, Archakov AI.

Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions.

Biochemistry (Mosc). 2006 Apr;71(4):354-60.

2. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI.

Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1.

Proteomics. 2005 Sep;5(14):3790-7.

3. Govorun VM, Lokhov PG, Moshkovskii SA, Momynaliev KT, Selesnyova OV, Kudryavtseva LV, Serebryakova MV, Tikhonova OV, Goufman EI, Archakov AI.

Comparative analysis of different typing methods for Helicobacter pylori clinical isolates.

Biochemistry (Mosc). 2004 May;69(5):536-41.

4. Lokhov PG, Tikhonova OV, Moshkovskii SA, Goufman EI, Serebriakova MV, Maksimov BI, Toropyguine IY, Zgoda VG, Govorun VM, Archakov AI.

Database search post-processing by neural network: Advanced facilities for identification of components in protein mixtures using mass spectrometric peptide mapping.

Proteomics. 2004 Mar;4(3):633-42.

5. Makarov OV, Govorun VM, Taranets IN, Goufman EI, Gritsai AN, Archakov AI.

[Early proteomics in ovarian cancer: myth or reality?]

Biomed Khim. 2003 Jan-Feb;49(1):2-7. Review. Russian.

6. Govorun VM, Moshkovskii SA, Tikhonova OV, Goufman EI, Serebryakova MV, Momynaliev KT, Lokhov PG, Khryapova EV, Kudryavtseva LV, Smirnova OV, Toropyguine IY, Maksimov BI, Archakov AI.

Comparative analysis of proteome maps of Helicobacter pylori clinical isolates.

Biochemistry (Mosc). 2003 Jan;68(1):42-9.

7. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL.

Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4510-5. Epub 2001 Mar 27.

8. Gartel AL, Goufman E, Najmabadi F, Tyner AL.

Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line.

Oncogene. 2000 Oct 26;19(45):5182-8.

9. Gartel AL, Najmabadi F, Goufman E, Tyner AL.

A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription.

Oncogene. 2000 Feb 17;19(7):961-4.

10. Gartel AL, Goufman E, Tevosian SG, Shih H, Yee AS, Tyner AL.

Activation and repression of p21(WAF1/CIP1) transcription by RB binding proteins.

Oncogene. 1998 Dec 31;17(26):3463-9.

11. Serfas MS, Goufman E, Feuerman MH, Gartel AL, Tyner AL.

p53-independent induction of p21WAF1/CIP1 expression in pericentral hepatocytes following carbon tetrachloride intoxication.

Cell Growth Differ. 1997 Sep;8(9):951-61.

12.Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, el-Deiry WS, Tyner AL. Related

p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line.

Exp Cell Res. 1996 Sep 15;227(2):171-81.

13. Akmaev IG, Goufman EI, Gusev AA, Markellov VV.

[The previously unknown biological characteristics of the neurons of the paraventricular hypothalamic nucleus]

Fiziol Zh SSSR Im I M Sechenova. 1992 Sep;78(9):63-8. Russian.

14. Reznikov AG, Akmaev IG, Fidelina OF, Gorbatyuk OS, Goufman EI, Gusev AA, Kalimullina LB, Pivnitskii KK, Sergeev VG, Vikhreva OV.

Metabolism of testosterone in discrete regions of the brain of rat embryos.

Neurosci Behav Physiol. 1991 May-Jun;21(3):259-63..

15. Goufman EI.

Cellular organization of the paraventricular nuclei of the rat hypothalamus.

Neurosci Behav Physiol. 1991 May-Jun;21(3):210-5.

16.Goufman EI.

[Cellular organization of paraventricular hypothalamic nuclei of the rat]

Arkh Anat Gistol Embriol. 1990 Jun;98(6):46-52. Russian.

17. Reznikov AG, Akmaev IG, Fidelina OF, Gorbatiuk OS, Goufman EI, Gusev AA, Kalimullina LB, Pivnitskii KK, Sergeev VG, Vikhreva OV.

[Testosterone metabolism in discrete areas of the brain in rat fetuses]

Probl Endokrinol (Mosk). 1990 May-Jun;36(3):57-61. Russian.

18. Akmaev IG, Goufman EI.

Experimental evidence for hypothalamic paraventricular nucleus involvement in the regulation of carbohydrate homeostasis.

Biomed Sci. 1990 Feb;1(2):193-8.

19. Gorbatiuk OS, Goufman EI, Gusev AA, Starosel'tseva LK, Akmaev IG.

[Reaction of specific cell populations of hypothalamic paraventricular nuclei of the rat to carbohydrate loading and fasting]

Biull Eksp Biol Med. 1989 Jul;108(7):105-7. Russian.

20. Goufman EI.

[Topography of the subnuclei of the paraventricular hypothalamic nucleus in rats and the sensitivity of their neurons to insulin deficiency]

Biull Eksp Biol Med. 1985 Feb;99(2):194-6. Russian.

PARTICIPATION IN INTERNATIONAL MEETINGS

1. XI International Congress of Cytochemistry. Cell Biology and Imaging for the New Century. UK, 2000

2 . Proteomics Congress. Munchen, Germany, 2002

RESEARCH SUPPORT

COMPLETED and ACTIVE

1. Federal target scientifically technical program of the Ministry of the industry and science, Russia “Researches and development in priority directions of development of a science and technics”, The state contract № 43.106.11.0005 (principal investigator) with 2002 to 2004 г.

2. The agreement №С-02-2003 Regional public Fund of assistance to domestic medicine (principal investigator) with 2003 to 2004 г.

3. Federal target scientifically technical program of the Ministry of the industry and science, Russia “The state support of the centers of collective using” with 2005

LIST OF CURRENT RESEARCH INTERESTS

Cancer Biology

Human Genetics

DNA repair and recombination

Apoptosis

Analytical cytology

Medical applications

Proteomics

Oleg Nikolaevich DARASHKEVICH

Date of birth: January 4,1954,Russia

Education: Graduated from Minsk State Medical Institute

1977

Post graduate study: Post graduate Course of Shemyakin Institute of Bioorganic Chemistry of the 1984 Academy of Sciences of USSR

Positions: Head of Project and General Director of Agro-Industrial Enterprise in Mogilev region of Belorus, suffered after Chernobyl Nuclear power plant disaster

Scientific adviser, Company Modus-Business, Minsk

Company SCIF, Bratislava.

Title: Ph.D in Medicine

Specialization Biochemistry, Biotechnology

Main publications

№	Patent Application Number		Patent Number		Titel
№	Номер	Дата публ.	Номер	Дата публ.	Titel
	20000706	2002.03.30			Device for continuous magnetic separation of liquid samples
	20000790	2002.03.30	6370	2004.09.30	Magnetic separator
	20000791	2002.03.30	6766	2005.03.30	Method for simultaneous detection of multiple components in the sample
	20000935	2002.06.30			Device and method for magnetic concentration of components in liquid samples
	20030359	2004.12.30			Method of sterilization of liquid samples
6	PCT/BY01/00011	2002.03.30			Device for continuous magnetic separation of liquid samples
7	PCT/BY01/00014	2002.03.30			A method and a device for simultaneous detection of multiple components in a mixture
8 USA	10/362,298				A method and a device for simultaneous detection of multiple components in a mixture
9 EP	ЕР1365241				A method and a device for simultaneous detection of multiple components in a mixture
10 ЕАПО			004670		Method and device for simultaneous detection of multiple components in the mixture
11 ЕАПО			004133		Device for continuous magnetic separation of components in liquid mixtures
12 РФ	2003125218		2280395		Method of sterilization of liquid samples
13	а20060719				Способ исследования Method of investigationвозникновения злокачественного процесса в организме и тест-система для его осуществления
14	а20060916				Способ лечения заболеваний с нарушением ангиогенеза и белковые комплексы для его осуществления (варианты)
15	а20061352				Способ профилактики и лечения заболеваний с нарушением ангиогенеза и белковый комплекс для его осуществления
16	а20070027				Способ лечения заболеваний с нарушением ангиогенеза
17	РСТ/ВУ2007/000002				Protein Complexes for Prevention and Treatment of Diseases with Angiogenesis Disorders